DARZALEX FASPRO® Is the First and only Treatment Approved by the U.S. FDA for Patients with High-Risk Smoldering Multiple Myeloma

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), offering a new treatment for high-risk smoldering multiple myeloma.

FDA Approves Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj for use in patients with high-risk smoldering multiple myeloma.

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

FDA Approves Darzalex Faspro in High-Risk Smoldering Multiple Myeloma

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma.

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this smoldering multiple myeloma population.